NVO - Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications | Benzinga
The skyrocketing demand for GLP-1 medications for weight loss is causing significant supply issues, often leaving type 2 diabetic patients without access to these critical drugs.
GLP-1 receptor agonists are blockbuster drugs due to their dual role in managing type 2 diabetes and aiding in weight reduction.
These medications induce the pancreas to produce more insulin and help curb hunger, slowing the movement of food from the stomach into the small intestine.
Also Read: Eli Lilly’s Famed Weight Loss Drug Zepbound Scores Chinese Approval.
The Forbes report adds that the popularity of such drugs has surged not only among diabetes patients and those with obesity ...